SE0002754D0 - New pharmaceutical combination formulation and method of treatment with the combination - Google Patents

New pharmaceutical combination formulation and method of treatment with the combination

Info

Publication number
SE0002754D0
SE0002754D0 SE0002754A SE0002754A SE0002754D0 SE 0002754 D0 SE0002754 D0 SE 0002754D0 SE 0002754 A SE0002754 A SE 0002754A SE 0002754 A SE0002754 A SE 0002754A SE 0002754 D0 SE0002754 D0 SE 0002754D0
Authority
SE
Sweden
Prior art keywords
combination
treatment
receptor
new pharmaceutical
formulation
Prior art date
Application number
SE0002754A
Other languages
English (en)
Swedish (sv)
Inventor
Kjell Steinar Sakariassen
Jan Svartengren
Sukhwinder Jossan
Bjoern Magnus Nilsson
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE0002754A priority Critical patent/SE0002754D0/xx
Publication of SE0002754D0 publication Critical patent/SE0002754D0/xx
Priority to JP2002514087A priority patent/JP2004504376A/ja
Priority to AU8273401A priority patent/AU8273401A/xx
Priority to HU0301346A priority patent/HUP0301346A3/hu
Priority to PL36030901A priority patent/PL360309A1/xx
Priority to EA200300183A priority patent/EA006604B1/ru
Priority to EP01961472A priority patent/EP1301476A1/en
Priority to IL15405701A priority patent/IL154057A0/xx
Priority to PCT/SE2001/001651 priority patent/WO2002008178A1/en
Priority to CA002411192A priority patent/CA2411192A1/en
Priority to MXPA03000548A priority patent/MXPA03000548A/es
Priority to KR1020037000321A priority patent/KR100845450B1/ko
Priority to CNB018131549A priority patent/CN1221254C/zh
Priority to NZ523216A priority patent/NZ523216A/en
Priority to YU2603A priority patent/YU2603A/sh
Priority to AU2001282734A priority patent/AU2001282734B2/en
Priority to BR0112661-0A priority patent/BR0112661A/pt
Priority to US09/908,801 priority patent/US6818639B2/en
Priority to ZA200210234A priority patent/ZA200210234B/en
Priority to NO20030304A priority patent/NO20030304L/no
Priority to HK04100306A priority patent/HK1057536A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE0002754A 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination SE0002754D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
BR0112661-0A BR0112661A (pt) 2000-07-21 2001-07-19 Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
MXPA03000548A MXPA03000548A (es) 2000-07-21 2001-07-19 Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
HU0301346A HUP0301346A3 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical composition and process for its preparation
PL36030901A PL360309A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
EA200300183A EA006604B1 (ru) 2000-07-21 2001-07-19 Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
EP01961472A EP1301476A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
IL15405701A IL154057A0 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation
JP2002514087A JP2004504376A (ja) 2000-07-21 2001-07-19 医薬製剤としてのセロトニンアゴニスト（５ｈｔ２）とアンタゴニスト（５ｈｔ６）の新規組み合わせ
CA002411192A CA2411192A1 (en) 2000-07-21 2001-07-19 Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation
AU8273401A AU8273401A (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
KR1020037000321A KR100845450B1 (ko) 2000-07-21 2001-07-19 약학적 제형물로서의 세로토닌 아고니스트 (5에이치티2)및 안타고니스트 (5에이치티6) 의 새로운 조합
CNB018131549A CN1221254C (zh) 2000-07-21 2001-07-19 新的作为药用配制品的血清素激动剂(5ht2)和拮抗剂(5ht6)复合剂
NZ523216A NZ523216A (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation
YU2603A YU2603A (sh) 2000-07-21 2001-07-19 Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija
AU2001282734A AU2001282734B2 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
US09/908,801 US6818639B2 (en) 2000-07-21 2001-07-20 Pharmaceutical combination formulation and method of treatment with the combination
ZA200210234A ZA200210234B (en) 2000-07-21 2002-12-18 New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation.
NO20030304A NO20030304L (no) 2000-07-21 2003-01-20 Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering
HK04100306A HK1057536A1 (en) 2000-07-21 2004-01-15 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination

Publications (1)

Publication Number Publication Date
SE0002754D0 true SE0002754D0 (sv) 2000-07-21

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination

Country Status (19)

Country Link
EP (1) EP1301476A1 (pt)
JP (1) JP2004504376A (pt)
KR (1) KR100845450B1 (pt)
CN (1) CN1221254C (pt)
AU (2) AU8273401A (pt)
BR (1) BR0112661A (pt)
CA (1) CA2411192A1 (pt)
EA (1) EA006604B1 (pt)
HK (1) HK1057536A1 (pt)
HU (1) HUP0301346A3 (pt)
IL (1) IL154057A0 (pt)
MX (1) MXPA03000548A (pt)
NO (1) NO20030304L (pt)
NZ (1) NZ523216A (pt)
PL (1) PL360309A1 (pt)
SE (1) SE0002754D0 (pt)
WO (1) WO2002008178A1 (pt)
YU (1) YU2603A (pt)
ZA (1) ZA200210234B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
JP4184077B2 (ja) * 2000-11-02 2008-11-19 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしての１−アリールまたは１−アルキルスルホニル−ヘテロシクリルベンザゾール
KR20040010709A (ko) * 2001-06-15 2004-01-31 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체 친화력을 갖는 4-피페라지닐인돌 유도체
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
MXPA04009318A (es) 2002-03-27 2005-01-25 Glaxo Group Ltd Derivados de quinolina y su uso como ligados 5-ht6.
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
ATE495737T1 (de) * 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
JP5579262B2 (ja) 2009-06-15 2014-08-27 武田薬品工業株式会社 ピラジノオキサゼピン誘導体
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
KR100845450B1 (ko) 2008-07-10
NZ523216A (en) 2005-05-27
EA200300183A1 (ru) 2003-08-28
NO20030304D0 (no) 2003-01-20
HUP0301346A3 (en) 2005-05-30
EA006604B1 (ru) 2006-02-24
BR0112661A (pt) 2003-06-24
IL154057A0 (en) 2003-07-31
AU8273401A (en) 2002-02-05
NO20030304L (no) 2003-03-12
HK1057536A1 (en) 2004-04-08
CN1443162A (zh) 2003-09-17
CN1221254C (zh) 2005-10-05
CA2411192A1 (en) 2002-01-31
YU2603A (sh) 2006-05-25
HUP0301346A2 (hu) 2003-08-28
PL360309A1 (en) 2004-09-06
AU2001282734B2 (en) 2006-10-12
MXPA03000548A (es) 2004-04-05
EP1301476A1 (en) 2003-04-16
ZA200210234B (en) 2004-03-18
WO2002008178A1 (en) 2002-01-31
KR20030036599A (ko) 2003-05-09
JP2004504376A (ja) 2004-02-12

Similar Documents

Publication Publication Date Title
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
CY1108201T1 (el) Συσκευες διαδερματικης απελευθερωσης οπιοειδους που ειναι ανθεκτικες στην παραβιαση
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
ATE423560T1 (de) Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
DE60322436D1 (de) Verabreichung von capsaicinoiden
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
HK1076379A1 (en) Use of a composition comprising anti-vla-1 antibody for the preparation of a pharmaceutical composition for the treatment of pulmonary fibrosis
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
SE9900961D0 (sv) Novel compounds
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
SE9802208D0 (sv) Novel compounds
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
SE9802209D0 (sv) Novel compounds
SE9902597D0 (sv) New use
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
DE60204694D1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE60004833D1 (de) Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
ATE260118T1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten